Expertise in
5
conditions

Jurgen Dunst

Arnold Heller Str. 3, 
Kiel, SH, DE 
Expertise in
5
conditions
Arnold Heller Str. 3, 
Kiel, SH, DE 

Overview

Jurgen Dunst practices practicing medicine in Kiel, Germany.

Dunst is highly rated in 5 conditions, according to our data. Their clinical expertise encompasses Ventricular Tachycardia, Breast Cancer, Arrhythmias, Mastectomy, and Osteotomy.

They are actively involved in clinical research, co-authoring 172 peer reviewed articles and participating in 8 clinical trials.

Locations

Arnold Heller Str. 3, Kiel, SH 24105, Germany
Other Locations
Head And Neck Surgery, Kiel, SH 24105, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2026
Intervention Type: Radiation, Drug
Study Drugs: Durvalumab, 5-Fluorouracil, Mitomycin C
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
Enrollment Status: Terminated
Publish Date: February 19, 2026
Intervention Type: Drug, Radiation
Study Phase: Phase 3
Radiosurgery for the Treatment of Refractory Ventricular Extrasystoles and Tachycardias (RAVENTA)
Radiosurgery for the Treatment of Refractory Ventricular Extrasystoles and Tachycardias (RAVENTA)
Enrollment Status: Completed
Publish Date: January 08, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors
An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 15, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 1
Hypofractionated Radiosurgery for Localised Prostate Cancer
Hypofractionated Radiosurgery for Localised Prostate Cancer
Enrollment Status: Completed
Publish Date: March 21, 2024
Intervention Type: Radiation
Study Phase: Not Applicable
Hypofractionated Radiosurgery for Localised Prostate Cancer
Hypofractionated Radiosurgery for Localised Prostate Cancer
Enrollment Status: Unknown
Publish Date: March 20, 2024
Intervention Type: Radiation
Study Phase: Not Applicable
Radiotherapy Related Skin Toxicity: Mepitel® Film vs. Standard Care in Patients With Locally Advanced Head-and-Neck Cancer
Radiotherapy Related Skin Toxicity: Mepitel® Film vs. Standard Care in Patients With Locally Advanced Head-and-Neck Cancer
Enrollment Status: Completed
Publish Date: March 24, 2020
Intervention Type: Other
Study Phase: Not Applicable
Clinical Testing on Newly Developed Monitoring Technology (The Cortrium C3 Device) for Continuous Measurements of ECG, Respiratory Rate, Body Surface Temperature and Accelerometer Data for Patients With Cancer
Clinical Testing on Newly Developed Monitoring Technology (The Cortrium C3 Device) for Continuous Measurements of ECG, Respiratory Rate, Body Surface Temperature and Accelerometer Data for Patients With Cancer
Enrollment Status: Completed
Publish Date: December 09, 2019
Intervention Type: Device
View 7 Less Clinical Trials

172 Total Publications

Intraprostatic gene therapy with aglatimagene as an adjunct to radiotherapy
Intraprostatic gene therapy with aglatimagene as an adjunct to radiotherapy
Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Published: June 16, 2026

Frequently Asked Questions about Jurgen Dunst

Is Jurgen Dunst a top-rated expert for Mastectomy?

MediFind is an objective health platform that identifies experts based on real-world data. Jurgen Dunst is classified as an Advanced expert for Mastectomy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jurgen Dunst participate in research or clinical trials?

Yes. Jurgen Dunst has published 172 articles and abstracts on conditions like Mastectomy. You can view a list of Jurgen Dunst's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dunst's expertise for a condition
ConditionClose
      View All 24 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile